vs
KEWAUNEE SCIENTIFIC CORP（KEQU）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
KEWAUNEE SCIENTIFIC CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的2.0倍（$70.1M vs $35.5M），KEWAUNEE SCIENTIFIC CORP净利率更高（3.5% vs -304.2%，领先307.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 46.8%），KEWAUNEE SCIENTIFIC CORP自由现金流更多（$-5.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 22.4%）
基沃尼科学公司是实验室家具、通风柜及一体化实验室基础设施解决方案的专业供应商，服务覆盖制药、生物技术、学术研究、医疗健康、工业研发等领域，核心市场为北美地区，同时正在稳步拓展全球客户网络。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
KEQU vs RXRX — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $70.1M | $35.5M |
| 净利润 | $2.4M | $-108.1M |
| 毛利率 | 28.1% | 59.8% |
| 营业利润率 | 5.9% | -304.8% |
| 净利率 | 3.5% | -304.2% |
| 营收同比 | 46.8% | 681.7% |
| 净利润同比 | -18.7% | 39.6% |
| 每股收益（稀释后） | $0.82 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $70.1M | $35.5M | ||
| Q3 25 | $71.1M | $5.2M | ||
| Q2 25 | $77.1M | $19.2M | ||
| Q1 25 | $67.2M | $14.7M | ||
| Q4 24 | $47.8M | $4.5M | ||
| Q3 24 | $48.4M | $26.1M | ||
| Q2 24 | $56.7M | $14.4M | ||
| Q1 24 | $46.8M | $13.8M |
| Q4 25 | $2.4M | $-108.1M | ||
| Q3 25 | $3.1M | $-162.3M | ||
| Q2 25 | $4.8M | $-171.9M | ||
| Q1 25 | $1.4M | $-202.5M | ||
| Q4 24 | $3.0M | $-178.9M | ||
| Q3 24 | $2.2M | $-95.8M | ||
| Q2 24 | $11.0M | $-97.5M | ||
| Q1 24 | $2.5M | $-91.4M |
| Q4 25 | 28.1% | 59.8% | ||
| Q3 25 | 29.4% | -183.8% | ||
| Q2 25 | 31.2% | -4.9% | ||
| Q1 25 | 27.4% | -48.0% | ||
| Q4 24 | 29.2% | -181.4% | ||
| Q3 24 | 25.8% | 53.7% | ||
| Q2 24 | 25.8% | 36.2% | ||
| Q1 24 | 25.7% | 19.1% |
| Q4 25 | 5.9% | -304.8% | ||
| Q3 25 | 6.8% | -3327.6% | ||
| Q2 25 | 11.0% | -916.8% | ||
| Q1 25 | 3.3% | -1297.9% | ||
| Q4 24 | 9.3% | -4042.4% | ||
| Q3 24 | 5.3% | -377.1% | ||
| Q2 24 | 9.8% | -697.4% | ||
| Q1 24 | 8.1% | -698.4% |
| Q4 25 | 3.5% | -304.2% | ||
| Q3 25 | 4.3% | -3135.3% | ||
| Q2 25 | 6.3% | -894.2% | ||
| Q1 25 | 2.0% | -1373.3% | ||
| Q4 24 | 6.3% | -3935.5% | ||
| Q3 24 | 4.5% | -367.5% | ||
| Q2 24 | 19.4% | -676.6% | ||
| Q1 24 | 5.4% | -662.4% |
| Q4 25 | $0.82 | $-0.17 | ||
| Q3 25 | $1.04 | $-0.36 | ||
| Q2 25 | $1.63 | $-0.41 | ||
| Q1 25 | $0.45 | $-0.50 | ||
| Q4 24 | $1.01 | $-0.56 | ||
| Q3 24 | $0.74 | $-0.34 | ||
| Q2 24 | $3.74 | $-0.40 | ||
| Q1 24 | $0.85 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.6M | $743.3M |
| 总债务越低越好 | $35.3M | $9.6M |
| 股东权益账面价值 | $69.9M | $1.1B |
| 总资产 | $189.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.50× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $12.6M | $743.3M | ||
| Q3 25 | $19.5M | $659.8M | ||
| Q2 25 | $14.9M | $525.1M | ||
| Q1 25 | $9.5M | $500.5M | ||
| Q4 24 | $26.0M | $594.4M | ||
| Q3 24 | $24.2M | $427.6M | ||
| Q2 24 | $23.3M | $474.3M | ||
| Q1 24 | $21.3M | $296.3M |
| Q4 25 | $35.3M | $9.6M | ||
| Q3 25 | $37.4M | $11.9M | ||
| Q2 25 | $37.7M | $14.2M | ||
| Q1 25 | $38.0M | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $69.9M | $1.1B | ||
| Q3 25 | $67.1M | $1.0B | ||
| Q2 25 | $64.5M | $919.1M | ||
| Q1 25 | $60.8M | $933.9M | ||
| Q4 24 | $59.3M | $1.0B | ||
| Q3 24 | $56.0M | $524.6M | ||
| Q2 24 | $54.8M | $584.4M | ||
| Q1 24 | $44.1M | $401.2M |
| Q4 25 | $189.1M | $1.5B | ||
| Q3 25 | $193.5M | $1.4B | ||
| Q2 25 | $194.7M | $1.3B | ||
| Q1 25 | $189.1M | $1.3B | ||
| Q4 24 | $134.5M | $1.4B | ||
| Q3 24 | $132.0M | $726.5M | ||
| Q2 24 | $134.8M | $775.9M | ||
| Q1 24 | $126.3M | $557.8M |
| Q4 25 | 0.50× | 0.01× | ||
| Q3 25 | 0.56× | 0.01× | ||
| Q2 25 | 0.58× | 0.02× | ||
| Q1 25 | 0.62× | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $-47.3M |
| 自由现金流率自由现金流/营收 | -8.3% | -133.1% |
| 资本支出强度资本支出/营收 | 2.2% | 3.5% |
| 现金转化率经营现金流/净利润 | -1.74× | — |
| 过去12个月自由现金流最近4个季度 | $5.1M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-4.3M | $-46.1M | ||
| Q3 25 | $5.8M | $-117.4M | ||
| Q2 25 | $9.4M | $-76.4M | ||
| Q1 25 | $-2.3M | $-132.0M | ||
| Q4 24 | $8.4M | $-115.4M | ||
| Q3 24 | $-794.0K | $-59.2M | ||
| Q2 24 | $1.1M | $-82.2M | ||
| Q1 24 | $9.5M | $-102.3M |
| Q4 25 | $-5.8M | $-47.3M | ||
| Q3 25 | $5.0M | $-117.6M | ||
| Q2 25 | $8.9M | $-79.6M | ||
| Q1 25 | $-3.0M | $-133.8M | ||
| Q4 24 | $7.8M | $-116.7M | ||
| Q3 24 | $-1.1M | $-63.8M | ||
| Q2 24 | $166.0K | $-83.4M | ||
| Q1 24 | $9.0M | $-109.0M |
| Q4 25 | -8.3% | -133.1% | ||
| Q3 25 | 7.1% | -2272.5% | ||
| Q2 25 | 11.5% | -413.9% | ||
| Q1 25 | -4.4% | -907.4% | ||
| Q4 24 | 16.2% | -2567.7% | ||
| Q3 24 | -2.2% | -244.6% | ||
| Q2 24 | 0.3% | -578.5% | ||
| Q1 24 | 19.3% | -789.9% |
| Q4 25 | 2.2% | 3.5% | ||
| Q3 25 | 1.1% | 4.7% | ||
| Q2 25 | 0.7% | 16.4% | ||
| Q1 25 | 1.0% | 12.4% | ||
| Q4 24 | 1.4% | 28.6% | ||
| Q3 24 | 0.6% | 17.5% | ||
| Q2 24 | 1.7% | 8.2% | ||
| Q1 24 | 1.0% | 48.2% |
| Q4 25 | -1.74× | — | ||
| Q3 25 | 1.87× | — | ||
| Q2 25 | 1.94× | — | ||
| Q1 25 | -1.67× | — | ||
| Q4 24 | 2.80× | — | ||
| Q3 24 | -0.36× | — | ||
| Q2 24 | 0.10× | — | ||
| Q1 24 | 3.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KEQU
| Transferred Over Time | $32.9M | 47% |
| Transferred At Point In Time | $22.3M | 32% |
| Other | $14.9M | 21% |
RXRX
暂无分部数据
